Home

Mesothelioma

Mesothelioma Treatment

Mesothelioma Specialists

Clinical Trials

Managing Your Care

Veterans Resources

MESOTHELIOMA MEDICAL JOURNAL ARTICLES

Abstracts of recent articles about mesothelioma in medical journals. Abstracts on continuing mesothelioma research presented at a American Society of Clinical Oncology meeting held in Orlando, FL. Many of these are available through PubMed, a search engine of the National Library of Medicine. Overview of mesothelioma in PDF format. See our page on how to read medical abstracts.

  1. Genome-Wide Profile of Pleural Mesothelioma versus Parietal and Visceral Pleura: The Emerging Gene Portrait of the Mesothelioma Phenotype

  2. Fatal hemopericardial tamponade due to primary pericardial mesothelioma: a case report

  3. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells

  4. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.

  5. Diagnosis and staging of pleural mesothelioma - English language abstract of a Japanese paper.

  6. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.

  7. Malignant mesothelioma - Review from the Orphanet Journal of Rare Diseases

  8. Malignant pleural mesothelioma: an update on biomarkers and treatment.

  9. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

  10. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells

  11. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma

  12. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma

  13. Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients

  14. Malignant pleural mesothelioma: computed tomography and correlation with histology.

  15. "Mucin-positive" epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall.

  16. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.

  17. Malignant mesothelioma following treatment for Hodgkin's disease

  18. Susceptibility and resistance in the genesis of asbestos-related mesothelioma

  19. Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study

  20. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.

  21. Asbestos-related cancer risk in the presence of asbestosis or pleural plaques

  22. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

  23. Multidisciplinary treatment of malignant pleural mesothelioma.

  24. An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers.

  25. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma.

  26. Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence.

  27. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.

  28. Malignant pleural mesothelioma: Computed tomography and correlation with histology

  29. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma

  30. Fibrous morphology: a chief determinent of the biological fate of asbestos in the lungs

  31. Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors.

  32. Bevacizumab raises risk of clots in cancer patients

  33. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.

  34. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.

  35. The mortality of women exposed environmentally and domestically to blue asbestos at Wittenoom, Western Australia.

  36. Case study: Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
  37. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

  38. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

  39. Recent advances in the treatment of malignant pleural mesothelioma.

  40. Mapping the risk of mesothelioma due to neighborhood asbestos exposure.

  41. Intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in malignant pleural mesothelioma

  42. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.

  43. Extended surgical staging for potentially resectable malignant pleural mesothelioma.

  44. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  45. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.

  46. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids.

  47. Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with malignant pleural mesothelioma (MPM): Outcomes on Expanded Access Program (EAP).

  48. Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP).

  49. Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM).

  50. A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).

  51. Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): Results of phase I study of SS1(dsFv)PE38 (SS1P).

  52. Single dose electron beam radiation therapy for tumor wound seeding prophylaxis in mesothelioma.

  53. Primary peritoneal mesothelioma: How aggressive should we be?

  54. Cisplatin Plus Pemetrexed (Alimta) shows promise in treatment of Mesothelioma

  55. Genetic predisposition and health effect of occupational exposure to asbestos.

  56. The economic costs of health service treatments for asbestos-related mesothelioma deaths.

  57. Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM).

  58. A phase II trial of Tetrathiomolybdate [TM] after cytoreductive surgery for malignant pleural mesothelioma (MPM).

  59. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.

  60. The role of Occupational Health and Safety Service in identifying past occupational exposure.

  61. Early-life family structure and cancer risk.

  62. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.

  63. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.

  64. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.

Proteomics and cancer research

Metastasis of mesothelioma

 

Professionals dedicated to fighting advanced mesthelioma

To receive a FREE Mesothelioma Web information packet** or to make a request, please fill out the following form :













Contact Us













**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

Resources

 

This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information: verify here

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376

Last updated Wed, 03/17/2010 - 10:13